Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Multicenter, Phase II Trial Assessing the Efficacy of Rituximab in HIV Infected Patients With Multicentric Castleman Disease Dependent on Chemotherapy (ANRS 117 Study, CastlemaB)|
- Sustained response rate of multicentric Castleman disease at day 60, after 4 infusions of rituximab
- One-year disease-free survival
- One-year event-free survival
- Relapse rate at day 365
- One-year lymphoma-free survival
- Tolerance of rituximab
- One-year overall survival
- Change in HHV-8 viral load within one year
- Change in lymphocyte B cell count within one year
|Study Start Date:||May 2003|
|Estimated Study Completion Date:||January 2006|
HIV-related multicentric Castleman disease (MCD) is a lymphoproliferative disorder characterized by lymphadenopathy with angiofollicular hyperplasia and plasma cell infiltration, associated with KSHV/HHV-8. Patients typically have systemic manifestations such as fever associated with lymphadenopathy, hepatosplenomegaly, respiratory symptoms, peripheral edema, cytopenia, hypergammaglobulinemia, hypoalbuminemia, and high levels of serum C reactive protein (CRP). Symptoms correlate with an important increase of KSHV/HHV-8 DNA in peripheral blood mononuclear cells. HIV-MCD is characterized by a rapidly progressive and often fatal course. HIV-MCD is often refractory to treatment. Vinca alkaloids produce frequent but short-lived responses, and most patients remain dependant upon chemotherapy.
Lymph nodes of patients with HIV-MCD specifically harbor the virus in B cells located in the mantle zone, which stain positively for the CD20 surface antigen. Rituximab, a humanized monoclonal anti-CD20 antibody, has been reported to be effective in some cases, with conflicting data in other cases. The optimal schedule of infusions remains unclear.
Kaposi's sarcoma is often associated with HIV-MCD, and the development of aggressive non-Hodgkin's lymphoma is not a rare outcome.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00127569
|Principal Investigator:||Eric Oksenhendler, M.D.||AP-HP Hopital Saint-Louis|